ProCE Banner Activity

New Advances in Relapsed/Refractory Multiple Myeloma: Current Guidance and Future Perspectives

In this interactive, on-demand Webcast, hematology experts review the current guidelines and new treatment advances for patients with relapsed/refractory multiple myeloma and discuss patient cases and new data from the 2020 ASCO Virtual Scientific Meeting.

Released: September 14, 2020

Expiration: September 13, 2021

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Natalie S. Callander

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

GlaxoSmithKline LLC

Sanofi Genzyme Corp

Learning Objectives

  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for R/R MM
  • Explain the mechanism of action of newer classes of agents indicated for and under investigation for R/R MM
  • Select optimal therapies for patients with heavily pretreated R/R MM based on individual patient and disease characteristics
  • Manage toxicities with newer agents and combination regimens in patients with heavily pretreated R/R MM
  • Identify patients with R/R MM who would be eligible for enrollment on late-phase clinical trials

Program Director Disclosure

Program Director

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received funds for research support (paid to the institution) from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Sanofi, and Takeda and consulting fees from AbbVie, Adaptive, Amgen, Celgene, Genentech, Janssen, Kite, MedImmune, Merck, Oncopeptides, and Takeda.

Faculty Disclosure

Primary Author

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has disclosed that she has received consulting fees from Cellectar.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.